Skip to main content

Intellia Therapeutics Inc Value Stock - Dividend - Research Selection

Intellia therapeutics inc

ISIN: US45826J1051 , WKN: A2AG6H

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


3 Gene Editing Stocks That Could Grow Your Wealth

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product

The FDA grants the Regenerative Medicine Advanced Therapy ("RMAT") designation to Kyvernas' (KYTX) lead candidate, KYV-101, for the treatment of patients suffering from refractory stiff-person syndrome.

All You Need to Know About Intellia Therapeutics (NTLA) Rating Upgrade to Strong Buy

Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 Profitable CRISPR Stocks Earning Analysts’ Praise

CRISPR technology, or Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool that allows scientists to make precise modifications to the DNA of living organisms. It’s one of the hottest trends in the stock market today, so I’ve made a list of three of the most profitable CRISPR stocks to consider. The CRISPR technology market is rapidly evolving, with significant advancements that hold immense potential for the future of medicine. As the technology become

The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024

Artificial intelligence stocks will be the choice of growth-oriented investors for years to come. But if you’re a buy-and-hold investor with above-average patience, this is a time to look for undervalued gene editing stocks. As the name suggests, gene editing companies offer the promise of altering the base instructions that the human body receives through its DNA. Since many life-threatening illnesses are genetically-based, the long-term implications of gene editing are profound. Moreover, many

The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger

An improbable but serious risk facing the company's investors just got minimized.

The 3 Best Gene Editing Stocks to Buy in July 2024

Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. With the technology, we can fix faulty genes, or replace them with healthier genes in an attempt to cure diseases or help the body fight disease. It holds massive promise for treating cancer, cystic fibrosis, diabetes, hemophilia and AIDS. Better, the U.S. FDA has already approved gene therapy treatments for forms of cancer, muscular atrophy, hemophilia and sickle cell anemia. B

3 Pharma Stocks Already Ushering in the Next Biotech Boom

Let’s get down to it: why should investors consider pharma stocks? Primarily, it comes down to the permanence of the underlying narrative. So long as humans are afflicted by various diseases, there will be a need for advanced pharmaceutical solutions. Therefore, money has been flowing into the broader biotechnology space and that will probably not fade anytime soon. The second reason? Pure numbers. According to Grand View Research, the global biotech market reached a valuation of $1.55 trillion